Skip to main
ATAI

ATAI Stock Forecast & Price Target

ATAI Analyst Ratings

Based on 7 analyst ratings
Strong Buy
Strong Buy 86%
Buy 14%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

AtaiBeckley is emerging as a significant player in the mental health therapeutics space, with a promising pipeline that includes BPL-003, VLS-01, and EMP-01 in various stages of development. The company has a strong focus on addressing the unmet needs of patients with treatment-resistant depression and social anxiety disorder. Despite some risks associated with the development of new psychiatric treatments, AtaiBeckley's innovative approach and potential for commercial success make it a compelling stock to watch.

Bears say

AtaiBeckley is facing a negative outlook due to their clinical trial results, as their Phase 3 trial for BPL-003 did not meet its primary endpoint, and their upcoming Phase 2 trial for VLS-01 is still in the early stages. While the company has seen positive Phase 2 data for EMP-01, the lack of significant pipeline advancements and the high cost of license fees and milestones suggest a potential struggle in commercialization and revenue generation in the future.

ATAI has been analyzed by 7 analysts, with a consensus rating of Strong Buy. 86% of analysts recommend a Strong Buy, 14% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Atai Life Sciences BV and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Atai Life Sciences BV (ATAI) Forecast

Analysts have given ATAI a Strong Buy based on their latest research and market trends.

According to 7 analysts, ATAI has a Strong Buy consensus rating as of May 21, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $16, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $16, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Atai Life Sciences BV (ATAI)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.